Efficacy News and Research

RSS

New self-expanding bioprosthetic valve used in TAVR fails to demonstrate non-inferiority

In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.

16 Oct 2020

Should Australia re-open international borders?

Australian scientist Jessica Liebig from the Commonwealth Scientific and Industrial Research Organisation (CSIRO), along with fellow researchers at the Queensland University of Technology and the University of New South Wales, studied the risks involved in re-opening the international borders for travelers to Australia.

15 Oct 2020

New technique uses ultrasound to provide non-invasive assessments of lung health

Researchers from North Carolina State University and the University of North Carolina have developed a technique that uses ultrasound to provide non-invasive assessments of pulmonary fibrosis and pulmonary edema.

15 Oct 2020

Small molecule restores normal heart development in animal model with rare genetic disorder

A research team at the Greenwood Genetic Center has successfully used small molecules to restore normal heart and valve development in an animal model for Mucolipidosis II (ML II), a rare genetic disorder. Progressive heart disease is commonly associated with ML II.

15 Oct 2020

SARS-CoV-2 may become endemic if reinfection proves commonplace, say researchers

To date, a few verified repeat SARS-CoV-2 infections have been documented around the world. "Should reinfection [with SARS-CoV-2] prove commonplace, and barring a highly effective vaccine delivered to most of the world's population, SARS-CoV-2 will likely become endemic," write Jeffrey Shaman and Marta Galanti in this Perspective.

15 Oct 2020

The COVID-19 vaccine pipeline

Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

14 Oct 2020

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

14 Oct 2020

Study reveals a list of medical procedures that pose COVID-19 risk to health-care providers

Autopsy, airway suctioning and cardiopulmonary resuscitation are among the list of medical procedures that pose a risk of spreading COVID-19 from a patient to their health-care provider by creating aerosols.

14 Oct 2020

Probability sampling to slow spread of SARS-CoV-2

Their study titled, “An Innovative Non-Pharmaceutical Intervention to Mitigate SARS-CoV02 Spread: Probability Sampling to Identify and Isolate Asymptomatic Cases,” was released at the pre-publication and pre-peer review site medRxiv*.

14 Oct 2020

NIH launches new study to streamline COVID-19 treatments for larger clinical studies

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials.

14 Oct 2020

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients.

14 Oct 2020

Sleep disorders common during COVID-19 pandemic

A recent study published on the preprint server medRxiv* in October 2020 reveals the significant prevalence of sleep abnormalities among the population in areas affected by COVID-19. This is likely to cause a heavy toll on mental and physical health if sustained over the long run.

13 Oct 2020

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

Researchers at The Medical Research Council Laboratory of Molecular Biology have conducted a study showing how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein interacts with host cell factors in ways that promote the formation of syncytia.

13 Oct 2020

In vitro BA-LRA can help detect small molecule drugs for drug-induced liver injury

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).

13 Oct 2020

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

A new study published on the preprint server bioRxiv in October 2020 shows that a combination of a new compound GNS561 and remdesivir act synergistically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This suggests that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.

12 Oct 2020

Optimizing allocation of future COVID-19 vaccine can double effectiveness

In anticipation of coronavirus disease (COVID-19) vaccine deployment, the Australian and US researchers utilized an age-structured mathematical model to appraise the potential benefits of optimizing age-specific dose allocation for suppressing SARS-CoV-2 transmission – and reaffirmed the notion that vaccination alone may be inadequate to achieve herd immunity in some settings. The study is currently available on the medRxiv* preprint server.

12 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

Efficacy News and Research

New self-expanding bioprosthetic valve used in TAVR fails to demonstrate non-inferiority

Should Australia re-open international borders?

New technique uses ultrasound to provide non-invasive assessments of lung health

Small molecule restores normal heart development in animal model with rare genetic disorder

SARS-CoV-2 may become endemic if reinfection proves commonplace, say researchers

The COVID-19 vaccine pipeline

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Study reveals a list of medical procedures that pose COVID-19 risk to health-care providers

Probability sampling to slow spread of SARS-CoV-2

NIH launches new study to streamline COVID-19 treatments for larger clinical studies

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

Sleep disorders common during COVID-19 pandemic

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

In vitro BA-LRA can help detect small molecule drugs for drug-induced liver injury

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

Optimizing allocation of future COVID-19 vaccine can double effectiveness

Nasal spray COVID-19 vaccine shows promising results in mice

Study shows evidence-based patient education is important in tinnitus

A new therapeutic approach for Epstein-Barr virus-associated tumors

New study may lead to more effective, personalized cancer immunotherapies

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News